Aflac Incorporated delivered solid earnings in the fourth quarter of 2025, with total revenues reaching $4.9 billion and net earnings at $1.4 billion. Adjusted earnings per diluted share saw a slight increase of 0.6% to $1.57. The company also reported strong sales growth in Aflac Japan, driven by its new cancer insurance product, and an increase in net earned premiums for Aflac U.S. Capital deployment included $800 million in share repurchases, and the board declared a 5.2% increase in the first quarter dividend.
Total revenues for Q4 2025 were $4.9 billion, a decrease from $5.4 billion in Q4 2024.
Net earnings for Q4 2025 were $1.4 billion, or $2.64 per diluted share, down from $1.9 billion, or $3.42 per diluted share, in Q4 2024.
Adjusted earnings per diluted share increased by 0.6% to $1.57 in Q4 2025.
Aflac Japan's new annualized premium sales increased by 15.7% in yen terms, and Aflac U.S. sales increased by 3.1%.
Aflac is committed to its strategy of creating long-term shareholder value, focusing on sales growth in Japan and profitable growth in the U.S., while maintaining strong capital management and a commitment to increasing dividends.
Analyze how earnings announcements historically affect stock price performance